Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

Levels of antibodies targeting the Epstein-Barr virus are not associated with disease activity among multiple sclerosis ...

For years scientists have suspected that the Epstein-Barr virus (EBV)—a type of herpesvirus that infects 94 percent of the ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

Autolus Therapeutics plc is continuing its work to become a pioneering cell therapy company in the space of AD. Learn more ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...

Scientists at UCSF have uncovered evidence that multiple sclerosis silently damages the brain years before diagnosis. By studying proteins in blood samples, they identified early immune signals and ...

One of the most common viruses in the world could be the cause of lupus, an autoimmune disease with wide-ranging symptoms, ...